45 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
company at any time during the six (6) months prior to such person’s hiring by Executive.
In this Agreement, “Restricted Person” means anyone employed
424B3
ADAP
Adaptimmune Therapeutics Plc
20 Apr 23
Prospectus supplement
4:32pm
that they have been able to in the past. In addition, if the merger is not completed, Adaptimmune and TCR2 may also encounter challenges in hiring qualified
S-4/A
ADAP
Adaptimmune Therapeutics Plc
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
that they have been able to in the past. In addition, if the merger is not completed, Adaptimmune and TCR2 may also encounter challenges in hiring qualified
S-4
ADAP
Adaptimmune Therapeutics Plc
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
extent that they have been able to in the past. In addition, if the merger is not completed, Adaptimmune and TCR2 may also encounter challenges in hiring
8-K
EX-10.01
nmwi ku7fbpu
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.1
b1d88c md4z9f
16 Dec 20
Departure of Directors or Certain Officers
5:01pm
8-K
EX-10.1
6mh0ys2dmgfmen
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-10.1
cn0dl
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-10.1
ntt1dmd
27 Jun 19
Departure of Directors or Certain Officers
8:08am